

Harry Sokol

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3791009/publications.pdf>

Version: 2024-02-01

256
papers

30,597
citations

8755

77
h-index

6024

165
g-index

275
all docs

275
docs citations

275
times ranked

31432
citing authors

#	ARTICLE	IF	CITATIONS
1	Role of adherent and invasive <i>Escherichia coli</i> in Crohn's disease: lessons from the postoperative recurrence model. <i>Gut</i> , 2023, 72, 39-48.	6.1	22
2	AhR/IL-22 pathway as new target for the treatment of post-infectious irritable bowel syndrome symptoms. <i>Gut Microbes</i> , 2022, 14, 2022997.	4.3	19
3	Evolution of FMT " From early clinical to standardized treatments. <i>Biologicals</i> , 2022, , .	0.5	3
4	Identification of Gene Expression Profiles Associated with an Increased Risk of Post-Operative Recurrence in Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 1269-1280.	0.6	15
5	Patient knowledge of gut microbiota and acceptability of fecal microbiota transplantation in various diseases. <i>Neurogastroenterology and Motility</i> , 2022, , e14320.	1.6	2
6	An appraisal of the frequency and severity of noninfectious manifestations in primary immunodeficiencies: A study of a national retrospective cohort of 1375 patients over 10 years. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 2116-2125.	1.5	7
7	Long-term diosmectite use does not alter the gut microbiota in adults with chronic diarrhea. <i>BMC Microbiology</i> , 2022, 22, 54.	1.3	1
8	Validation of the Performance of A1HPV6, a Triage Blood Test for the Early Diagnosis and Prognosis of SARS-CoV-2 Infection. , 2022, 1, 393-402.		3
9	Impact of the Ileal Microbiota on Surgical Site Infections in Crohn's Disease: A Nationwide Prospective Cohort. <i>Journal of Crohn's and Colitis</i> , 2022, , .	0.6	3
10	Gut Microbiota Reprogramming of Tryptophan Metabolism During Pregnancy Shapes Host Insulin Resistance. <i>Gastroenterology</i> , 2022, , .	0.6	2
11	Microbiota in Neuroinflammation and Synaptic dysfunction: a focus on Alzheimer's disease. <i>Molecular Neurodegeneration</i> , 2022, 17, 19.	4.4	89
12	Alteration of the gut microbiota following SARS-CoV-2 infection correlates with disease severity in hamsters. <i>Gut Microbes</i> , 2022, 14, 2018900.	4.3	47
13	Modern Metaproteomics: A Unique Tool to Characterize the Active Microbiome in Health and Diseases, and Pave the Road towards New Biomarkers" Example of Crohn's Disease and Ulcerative Colitis Flare-Ups. <i>Cells</i> , 2022, 11, 1340.	1.8	11
14	Human CD4 ⁺ CD81 ⁺ Tregs induced by <i>Faecalibacterium prausnitzii</i> protect against intestinal inflammation. <i>JCI Insight</i> , 2022, 7, .	2.3	23
15	SER-109 for Recurrent <i>Clostridioides difficile</i> Infection. <i>New England Journal of Medicine</i> , 2022, 386, 1956-1958.	13.9	1
16	On the Determinants of IDO Activity in Patients With Familial Mediterranean Fever. <i>Modern Rheumatology</i> , 2022, , .	0.9	0
17	Fecal microbiota and bile acids in IBD patients undergoing screening for colorectal cancer. <i>Gut Microbes</i> , 2022, 14, .	4.3	20
18	Deletion of both Dectin-1 and Dectin-2 affects the bacterial but not fungal gut microbiota and susceptibility to colitis in mice. <i>Microbiome</i> , 2022, 10, .	4.9	7

#	ARTICLE	IF	CITATIONS
19	Alteration of the gut microbiota's composition and metabolic output correlates with COVID-19-like severity in obese NASH hamsters. <i>Gut Microbes</i> , 2022, 14, .	4.3	8
20	A Scoring System to Determine Patients' Risk of Colectomy Within 1 Year After Hospital Admission for Acute Severe Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1602-1610.e1.	2.4	26
21	Infections in Patients with Chronic Granulomatous Disease Treated with Tumor Necrosis Factor Alpha Blockers for Inflammatory Complications. <i>Journal of Clinical Immunology</i> , 2021, 41, 185-193.	2.0	15
22	A standardised model for stool banking for faecal microbiota transplantation: a consensus report from a multidisciplinary UEG working group. <i>United European Gastroenterology Journal</i> , 2021, 9, 229-247.	1.6	66
23	Microbiota tryptophan metabolism induces aryl hydrocarbon receptor activation and improves alcohol-induced liver injury. <i>Gut</i> , 2021, 70, 1299-1308.	6.1	92
24	Tryptophan Metabolism as a Pharmacological Target. <i>Trends in Pharmacological Sciences</i> , 2021, 42, 60-73.	4.0	135
25	Gut microbiota-derived metabolites as central regulators in metabolic disorders. <i>Gut</i> , 2021, 70, 1174-1182.	6.1	519
26	Tryptophan metabolites get the gut moving. <i>Cell Host and Microbe</i> , 2021, 29, 145-147.	5.1	22
27	PRODIGE 59-DURIGAST trial: A randomised phase II study evaluating FOLFIRI + Durvalumab ± Tremelimumab in second-line of patients with advanced gastric cancer. <i>Digestive and Liver Disease</i> , 2021, 53, 420-426.	0.4	10
28	SARS-CoV-2 vaccines and donor recruitment for FMT. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 264-266.	3.7	5
29	Recipient factors in faecal microbiota transplantation: one stool does not fit all. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021, 18, 503-513.	8.2	74
30	Impact of gut fungal and bacterial communities on the outcome of allogeneic hematopoietic cell transplantation. <i>Mucosal Immunology</i> , 2021, 14, 1127-1132.	2.7	9
31	Gut microbiota-derived short-chain fatty acids regulate IL-17 production by mouse and human intestinal T cells. <i>Cell Reports</i> , 2021, 36, 109332.	2.9	114
32	Butyrate, a new microbiota-dependent player in CD8+ T cells immunity and cancer therapy?. <i>Cell Reports Medicine</i> , 2021, 2, 100328.	3.3	19
33	The use of Faecal Microbiota Transplantation (FMT) in Europe: A Europe-wide survey. <i>Lancet Regional Health - Europe</i> , The, 2021, 9, 100181.	3.0	43
34	Immune-mediated inflammatory diseases and nutrition: results from an online survey on patients' practices and perceptions. <i>BMC Nutrition</i> , 2021, 7, 38.	0.6	8
35	Blockage of bacterial FimH prevents mucosal inflammation associated with Crohn's disease. <i>Microbiome</i> , 2021, 9, 176.	4.9	22
36	Postbiotics "when simplification fails to clarify. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021, 18, 825-826.	8.2	63

#	ARTICLE	IF	CITATIONS
37	Pembrolizumab with Capox Bevacizumab in patients with microsatellite stable metastatic colorectal cancer and a high immune infiltrate: The FFCO 1703-POCHI trial. <i>Digestive and Liver Disease</i> , 2021, 53, 1254-1259.	0.4	5
38	Osteoarthritis and gut microbiome. <i>Joint Bone Spine</i> , 2021, 88, 105203.	0.8	10
39	SARS-CoV-2 infection in nonhuman primates alters the composition and functional activity of the gut microbiota. <i>Gut Microbes</i> , 2021, 13, 1-19.	4.3	75
40	Vasoactive intestinal peptide promotes host defense against enteric pathogens by modulating the recruitment of group 3 innate lymphoid cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	30
41	Circulating bile acids concentration is predictive of coronary artery disease in human. <i>Scientific Reports</i> , 2021, 11, 22661.	1.6	22
42	Reporting guidelines for human microbiome research: the STORMS checklist. <i>Nature Medicine</i> , 2021, 27, 1885-1892.	15.2	170
43	Association Between Microscopic Lesions at Ileal Resection Margin and Recurrence After Surgery in Patients With Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 141-149.e2.	2.4	32
44	Prominence of ileal mucosa-associated microbiota to predict postoperative endoscopic recurrence in Crohn's disease. <i>Gut</i> , 2020, 69, 462-472.	6.1	76
45	Fungi participate in the dysbiosis of gut microbiota in patients with primary sclerosing cholangitis. <i>Gut</i> , 2020, 69, 92-102.	6.1	136
46	Efficacy of Tumor Necrosis Factor Antagonist Treatment in Patients With Refractory Ulcerative Proctitis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 620-627.e1.	2.4	21
47	Nancy Index Scores of Chronic Inflammatory Bowel Disease Activity Associate With Development of Colorectal Neoplasia. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 150-157.e1.	2.4	23
48	Gut microbiota in PSC: From association to possible causality. Commentary to "Gut pathobionts underlie intestinal barrier dysfunction and liver T helper 17 cell immune response in primary sclerosing cholangitis" by Nakamoto et al., <i>Nature Microbiology</i> , January 2019. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2020, 44, 123-125.	0.7	3
49	Gut microbiome alterations in anti-NMDA receptor encephalitis: caveats for result interpretation. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 153-154.	1.7	1
50	The enemy from within: a prophage of <i>Roseburia intestinalis</i> systematically turns lytic in the mouse gut, driving bacterial adaptation by CRISPR spacer acquisition. <i>ISME Journal</i> , 2020, 14, 771-787.	4.4	48
51	Impact of Aphthous Colitis at Diagnosis on Crohn's Disease Outcomes. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 342-350.	0.6	2
52	Increased incidence of systemic serious viral infections in patients with inflammatory bowel disease associates with active disease and use of thiopurines. <i>United European Gastroenterology Journal</i> , 2020, 8, 303-313.	1.6	79
53	A clinical decision support tool may help to optimise vedolizumab therapy in Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 553-564.	1.9	30
54	Butyrate mediates anti-inflammatory effects of <i>Faecalibacterium prausnitzii</i> in intestinal epithelial cells through <i>Dact3</i> . <i>Gut Microbes</i> , 2020, 12, 1826748.	4.3	90

#	ARTICLE	IF	CITATIONS
55	Tofacitinib treatment alters mucosal immunity and gut microbiota during experimental arthritis. <i>Clinical and Translational Medicine</i> , 2020, 10, e163.	1.7	5
56	Drug Mimicry: Promiscuous Receptors PXR and AhR, and Microbial Metabolite Interactions in the Intestine. <i>Trends in Pharmacological Sciences</i> , 2020, 41, 900-908.	4.0	35
57	Aryl hydrocarbon receptor ligand production by the gut microbiota is decreased in celiac disease leading to intestinal inflammation. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	98
58	Mechanisms underpinning the efficacy of faecal microbiota transplantation in treating gastrointestinal disease. <i>Therapeutic Advances in Gastroenterology</i> , 2020, 13, 175628482094690.	1.4	21
59	The Gut Microbiota at the Service of Immunometabolism. <i>Cell Metabolism</i> , 2020, 32, 514-523.	7.2	152
60	Linking Strain Engraftment in Fecal Microbiota Transplantation With Maintenance of Remission in Crohn's Disease. <i>Gastroenterology</i> , 2020, 159, 2193-2202.e5.	0.6	41
61	Glycans as Immune Checkpoints: Removal of Branched N-glycans Enhances Immune Recognition Preventing Cancer Progression. <i>Cancer Immunology Research</i> , 2020, 8, 1407-1425.	1.6	33
62	Antibiotics: a trigger for inflammatory bowel disease?. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 956-957.	3.7	8
63	Expert centres for faecal microbiota transplantation: The guarantee for safe and effective use of faecal transplants. <i>United European Gastroenterology Journal</i> , 2020, 8, 1145-1146.	1.6	1
64	Increased risk of permanent stoma in Crohn's disease associated with hidradenitis suppurativa: a case-control study. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 303-310.	1.9	1
65	Human microbial metabolite mimicry as a strategy to expand the chemical space of potential drugs. <i>Drug Discovery Today</i> , 2020, 25, 1575-1579.	3.2	4
66	Impact of fecal microbiota transplantation on chronic recurrent pouchitis in ulcerative colitis with ileo-anal anastomosis: study protocol for a prospective, multicenter, double-blind, randomized, controlled trial. <i>Trials</i> , 2020, 21, 455.	0.7	4
67	Donated stool for faecal microbiota transplantation is not a drug, but guidance and regulation are needed. <i>United European Gastroenterology Journal</i> , 2020, 8, 353-354.	1.6	0
68	Screening of faecal microbiota transplant donors during the COVID-19 outbreak: suggestions for urgent updates from an international expert panel. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 430-432.	3.7	108
69	Ozone-Induced Aryl Hydrocarbon Receptor Activation Controls Lung Inflammation via Interleukin-22 Modulation. <i>Frontiers in Immunology</i> , 2020, 11, 144.	2.2	33
70	Fecal microbiota transplantation in gastrointestinal disorders: time for precision medicine. <i>Genome Medicine</i> , 2020, 12, 58.	3.6	33
71	Potential Causes and Consequences of Gastrointestinal Disorders during a SARS-CoV-2 Infection. <i>Cell Reports</i> , 2020, 32, 107915.	2.9	113
72	Reorganisation of faecal microbiota transplant services during the COVID-19 pandemic. <i>Gut</i> , 2020, 69, 1555-1563.	6.1	110

#	ARTICLE	IF	CITATIONS
73	Gut microbiota-derived metabolites as key actors in inflammatory bowel disease. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020, 17, 223-237.	8.2	893
74	Maintenance of Remission Among Patients With Inflammatory Bowel Disease After Vedolizumab Discontinuation: A Multicentre Cohort Study. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 896-903.	0.6	12
75	Fecal microbiota transplantation to maintain remission in Crohn's disease: a pilot randomized controlled study. <i>Microbiome</i> , 2020, 8, 12.	4.9	203
76	Dendritic cell-derived hepcidin sequesters iron from the microbiota to promote mucosal healing. <i>Science</i> , 2020, 368, 186-189.	6.0	80
77	Specific changes in faecal microbiota are associated with familial Mediterranean fever. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1398-1404.	0.5	18
78	Baseline microbiota composition modulates antibiotic-mediated effects on the gut microbiota and host. <i>Microbiome</i> , 2019, 7, 111.	4.9	50
79	Oral delivery of pancreatitis-associated protein by <i>Lactococcus lactis</i> displays protective effects in dinitrobenzenesulfonic acid-induced colitis model and is able to modulate the composition of the microbiota. <i>Environmental Microbiology</i> , 2019, 21, 4020-4031.	1.8	15
80	A necessary discussion after transmission of multidrug-resistant organisms through faecal microbiota transplantations. <i>Lancet Infectious Diseases</i> , The, 2019, 19, 1161-1162.	4.6	8
81	PS-126-Fungi participate in the dysbiosis of gut microbiota in patients with primary sclerosing cholangitis. <i>Journal of Hepatology</i> , 2019, 70, e78.	1.8	1
82	Faecalibacterium prausnitzii Skews Human DC to Prime IL10-Producing T Cells Through TLR2/6/JNK Signaling and IL-10, IL-27, CD39, and IDO-1 Induction. <i>Frontiers in Immunology</i> , 2019, 10, 143.	2.2	72
83	Fecal Microbiota Transplantation for Ulcerative Colitis. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 2240.	3.8	6
84	Genetic effects on the commensal microbiota in inflammatory bowel disease patients. <i>PLoS Genetics</i> , 2019, 15, e1008018.	1.5	35
85	Association of Genetic Variants in <i>NUDT15</i> With Thiopurine-Induced Myelosuppression in Patients With Inflammatory Bowel Disease. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 773.	3.8	129
86	Fecal microbiota transplantation before or after allogeneic hematopoietic transplantation in patients with hematologic malignancies carrying multidrug-resistance bacteria. <i>Haematologica</i> , 2019, 104, 1682-1688.	1.7	91
87	T cell clonal expansions in ileal Crohn's disease are associated with smoking behaviour and postoperative recurrence. <i>Gut</i> , 2019, 68, 1961-1970.	6.1	35
88	The gut mycobiota: insights into analysis, environmental interactions and role in gastrointestinal diseases. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2019, 16, 331-345.	8.2	226
89	Stool for fecal microbiota transplantation should be classified as a transplant product and not as a drug. <i>United European Gastroenterology Journal</i> , 2019, 7, 1408-1410.	1.6	15
90	International consensus conference on stool banking for faecal microbiota transplantation in clinical practice. <i>Gut</i> , 2019, 68, 2111-2121.	6.1	290

#	ARTICLE	IF	CITATIONS
91	Intestinal dysbiosis in inflammatory bowel disease associated with primary immunodeficiency. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 775-778.e6.	1.5	28
92	Bacteria engineered to produce IL-22 in intestine induce expression of REG3G to reduce ethanol-induced liver disease in mice. <i>Gut</i> , 2019, 68, 1504-1515.	6.1	202
93	Validation of a global quantitative analysis methodology of tryptophan metabolites in mice using LC-MS. <i>Talanta</i> , 2019, 195, 593-598.	2.9	33
94	The regenerating family member 3 β instigates IL-17A-mediated neutrophil recruitment downstream of NOD1/2 signalling for controlling colonisation resistance independently of microbiota community structure. <i>Gut</i> , 2019, 68, 1190-1199.	6.1	14
95	Roux-en-Y Gastric-Bypass and sleeve gastrectomy induces specific shifts of the gut microbiota without altering the metabolism of bile acids in the intestinal lumen. <i>International Journal of Obesity</i> , 2019, 43, 428-431.	1.6	19
96	The Gut Microbiome in Inflammatory Bowel Disease. , 2019, , 347-377.		0
97	Impact of Gut Mycobiota Composition on Outcomes after Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2019, 134, 194-194.	0.6	0
98	Beyond metagenomics, metatranscriptomics illuminates microbiome functionality in IBD. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2018, 15, 193-194.	8.2	30
99	Aryl hydrocarbon receptor and intestinal immunity. <i>Mucosal Immunology</i> , 2018, 11, 1024-1038.	2.7	326
100	Impact of vedolizumab therapy on extra-intestinal manifestations in patients with inflammatory bowel disease: a multicentre cohort study nested in the <sc>OBSERV</sc>â€<sc>IBD</sc> cohort. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 485-493.	1.9	91
101	Interleukin-22-deficiency and microbiota contribute to the exacerbation of <i>Toxoplasma gondii</i> -induced intestinal inflammation. <i>Mucosal Immunology</i> , 2018, 11, 1181-1190.	2.7	29
102	Differences in epidemiological features between ulcerative colitis and Crohnâ€™s disease: The early life-programmed versus late dysbiosis hypothesis. <i>Medical Hypotheses</i> , 2018, 115, 19-21.	0.8	11
103	The microbiota: an underestimated actor in radiation-induced lesions?. <i>Gut</i> , 2018, 67, 1-2.	6.1	54
104	Features of Autoimmune Pancreatitis Associated With Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 59-67.	2.4	52
105	Mucosa-associated microbiota dysbiosis in colitis associated cancer. <i>Gut Microbes</i> , 2018, 9, 131-142.	4.3	142
106	Card9 mediates susceptibility to intestinal pathogens through microbiota modulation and control of bacterial virulence. <i>Gut</i> , 2018, 67, 1836-1844.	6.1	38
107	Specificities of the intestinal microbiota in patients with inflammatory bowel disease and <i>Clostridium difficile</i> infection. <i>Gut Microbes</i> , 2018, 9, 55-60.	4.3	85
108	Clinical and multi-omics cross-phenotyping of patients with autoimmune and autoinflammatory diseases: the observational TRANSIMMUNOM protocol. <i>BMJ Open</i> , 2018, 8, e021037.	0.8	17

#	ARTICLE	IF	CITATIONS
109	Diet-Induced Dysbiosis and Genetic Background Synergize With Cystic Fibrosis Transmembrane Conductance Regulator Deficiency to Promote Cholangiopathy in Mice. <i>Hepatology Communications</i> , 2018, 2, 1533-1549.	2.0	28
110	Inhibitory Effect of Ursodeoxycholic Acid on <i>Clostridium difficile</i> Germination Is Insufficient to Prevent Colitis: A Study in Hamsters and Humans. <i>Frontiers in Microbiology</i> , 2018, 9, 2849.	1.5	11
111	Male gender, active smoking and previous intestinal resection are risk factors for post-operative endoscopic recurrence in Crohn's disease: results from a prospective cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 924-932.	1.9	71
112	Expression of CCR6 and CXCR6 by Gut-Derived CD4 ⁺ /CD8 ⁺ T-Regulatory Cells, Which Are Decreased in Blood Samples From Patients With Inflammatory Bowel Diseases. <i>Gastroenterology</i> , 2018, 155, 1205-1217.	0.6	42
113	Clinical activity is an independent risk factor of ischemic heart and cerebrovascular arterial disease in patients with inflammatory bowel disease. <i>PLoS ONE</i> , 2018, 13, e0201991.	1.1	29
114	Enterobacteriaceae are essential for the modulation of colitis severity by fungi. <i>Microbiome</i> , 2018, 6, 152.	4.9	143
115	Inter-kingdom effect on epithelial cells of the N-Acyl homoserine lactone 3-oxo-C12:2, a major quorum-sensing molecule from gut microbiota. <i>PLoS ONE</i> , 2018, 13, e0202587.	1.1	43
116	Genetic deficiency of indoleamine 2,3-dioxygenase promotes gut microbiota-mediated metabolic health. <i>Nature Medicine</i> , 2018, 24, 1113-1120.	15.2	193
117	Impaired Aryl Hydrocarbon Receptor Ligand Production by the Gut Microbiota Is a Key Factor in Metabolic Syndrome. <i>Cell Metabolism</i> , 2018, 28, 737-749.e4.	7.2	356
118	Risk of serious infection in healthcare workers with inflammatory bowel disease: a case-control study of the Groupe d'Etude Thérapeutique des Affections Inflammatoires du tube Digestif (GETAID). <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 713-722.	1.9	10
119	Nucleotide-Binding Domain Leucine-Rich Repeat Containing Proteins and Intestinal Microbiota: Pivotal Players in Colitis and Colitis-Associated Cancer Development. <i>Frontiers in Immunology</i> , 2018, 9, 1039.	2.2	6
120	A Versatile New Model of Chemically Induced Chronic Colitis Using an Outbred Murine Strain. <i>Frontiers in Microbiology</i> , 2018, 9, 565.	1.5	30
121	<i>Bilophila wadsworthia</i> aggravates high fat diet induced metabolic dysfunctions in mice. <i>Nature Communications</i> , 2018, 9, 2802.	5.8	317
122	Gut Microbiota-Stimulated Innate Lymphoid Cells Support β -Defensin 14 Expression in Pancreatic Endocrine Cells, Preventing Autoimmune Diabetes. <i>Cell Metabolism</i> , 2018, 28, 557-572.e6.	7.2	84
123	Phages infecting <i>Faecalibacterium prausnitzii</i> belong to novel viral genera that help to decipher intestinal viromes. <i>Microbiome</i> , 2018, 6, 65.	4.9	98
124	Gut Microbiota Regulation of Tryptophan Metabolism in Health and Disease. <i>Cell Host and Microbe</i> , 2018, 23, 716-724.	5.1	1,442
125	Insights into the genetic epidemiology of Crohn's and rare diseases in the Ashkenazi Jewish population. <i>PLoS Genetics</i> , 2018, 14, e1007329.	1.5	66
126	Abstract 585: Card9 Deficiency Accelerates Experimental Atherosclerosis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2018, 38, .	1.1	0

#	ARTICLE	IF	CITATIONS
127	Fungal microbiota dysbiosis in IBD. <i>Gut</i> , 2017, 66, 1039-1048.	6.1	939
128	European consensus conference on faecal microbiota transplantation in clinical practice. <i>Gut</i> , 2017, 66, 569-580.	6.1	793
129	A microbial signature for Crohn's disease. <i>Gut</i> , 2017, 66, 813-822.	6.1	657
130	<i>Clostridium difficile</i> infection in acute flares of inflammatory bowel disease: A prospective study. <i>Digestive and Liver Disease</i> , 2017, 49, 643-646.	0.4	57
131	Caspase recruitment domain 9, microbiota, and tryptophan metabolism. <i>Current Opinion in Clinical Nutrition and Metabolic Care</i> , 2017, 20, 243-247.	1.3	17
132	Inflammatory Bowel Diseases: How to Identify High-Risk Patients. , 2017, , 653-660.		0
133	One-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multicentre cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 310-321.	1.9	128
134	Fecal Microbiota Transplantation: Do We Need Harmonization?. <i>Clinical Infectious Diseases</i> , 2017, 64, 1292-1292.	2.9	8
135	Faecal microbiota study reveals specific dysbiosis in spondyloarthritis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1614-1622.	0.5	266
136	Chronic Granulomatous Disease in Patients Reaching Adulthood: A Nationwide Study in France. <i>Clinical Infectious Diseases</i> , 2017, 64, 767-775.	2.9	57
137	Postoperative Complications after Ileocecal Resection in Crohn's Disease: A Prospective Study From the REMIND Group. <i>American Journal of Gastroenterology</i> , 2017, 112, 337-345.	0.2	138
138	Efficacy and safety of golimumab in Crohn's disease: a French national retrospective study. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 1077-1084.	1.9	23
139	Microbiota in digestive cancers: our new partner?. <i>Carcinogenesis</i> , 2017, 38, 1157-1166.	1.3	14
140	Using murine colitis models to analyze probiotics-host interactions. <i>FEMS Microbiology Reviews</i> , 2017, 41, S49-S70.	3.9	47
141	The Presence of Adherent-Invasive <i>Escherichia Coli</i> (AIEC) on the Surgical Specimen is a Predictor of Severe Endoscopic Postoperative Recurrence in Ileal Crohn's Disease. <i>Gastroenterology</i> , 2017, 152, S9.	0.6	1
142	Probiotic Strain <i>Lactobacillus casei</i> BL23 Prevents Colitis-Associated Colorectal Cancer. <i>Frontiers in Immunology</i> , 2017, 8, 1553.	2.2	156
143	Functional Characterization of Novel <i>Faecalibacterium prausnitzii</i> Strains Isolated from Healthy Volunteers: A Step Forward in the Use of <i>F. prausnitzii</i> as a Next-Generation Probiotic. <i>Frontiers in Microbiology</i> , 2017, 8, 1226.	1.5	320
144	New Insights into the Diversity of the Genus <i>Faecalibacterium</i> . <i>Frontiers in Microbiology</i> , 2017, 8, 1790.	1.5	71

#	ARTICLE	IF	CITATIONS
145	Experimental colitis delays and reduces the severity of collagen-induced arthritis in mice. PLoS ONE, 2017, 12, e0184624.	1.1	10
146	Bifidobacterium animalis ssp. lactis CNCM-I2494 Restores Gut Barrier Permeability in Chronically Low-Grade Inflamed Mice. Frontiers in Microbiology, 2016, 7, 608.	1.5	50
147	Impact on Life Expectancy of Withdrawing Thiopurines in Patients with Crohn's Disease in Sustained Clinical Remission: A Lifetime Risk-Benefit Analysis. PLoS ONE, 2016, 11, e0157191.	1.1	19
148	Mature CD8 + T cell clonal expansion in the oral cavity and digestive tract: a severe lymphoid malignancy that mimics Crohn's disease. Clinical Case Reports (discontinued), 2016, 4, 1088-1090.	0.2	1
149	Fecal Microbiota Transplantation is Safe and Efficacious for Recurrent or Refractory Clostridium difficile Infection in Patients with Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2016, 22, 2402-2409.	0.9	143
150	1120 Incidence and Risk Factors of Serious Viral Infections in Inflammatory Bowel Disease. Gastroenterology, 2016, 150, S225.	0.6	0
151	Mo1852 Impact of Fertility Treatment on Inflammatory Bowel Disease Outcomes. Gastroenterology, 2016, 150, S795.	0.6	0
152	Effectiveness and Safety of Vedolizumab Induction Therapy for Patients With Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology, 2016, 14, 1593-1601.e2.	2.4	168
153	CARD9 impacts colitis by altering gut microbiota metabolism of tryptophan into aryl hydrocarbon receptor ligands. Nature Medicine, 2016, 22, 598-605.	15.2	1,001
154	Adalimumab or infliximab as monotherapy, or in combination with an immunomodulator, in the treatment of Crohn's disease. Alimentary Pharmacology and Therapeutics, 2016, 44, 1102-1113.	1.9	42
155	Enterococcus hirae and Barnesiella intestinihominis Facilitate Cyclophosphamide-Induced Therapeutic Immunomodulatory Effects. Immunity, 2016, 45, 931-943.	6.6	645
156	Fecal microbiota transplantation in inflammatory bowel disease: the quest for the holy grail. Mucosal Immunology, 2016, 9, 1360-1365.	2.7	64
157	Editorial: mongersen in Crohn's disease " a new contribution to the beginning of a long-awaited therapeutic revolution?. Alimentary Pharmacology and Therapeutics, 2016, 43, 838-839.	1.9	0
158	Faecalibacterium prausnitzii A2-165 has a high capacity to induce IL-10 in human and murine dendritic cells and modulates T cell responses. Scientific Reports, 2016, 6, 18507.	1.6	174
159	Anti-nociceptive effect of Faecalibacterium prausnitzii in non-inflammatory IBS-like models. Scientific Reports, 2016, 6, 19399.	1.6	72
160	Decreased tryptophan and increased kynurenine levels in mastocytosis associated with digestive symptoms. Allergy: European Journal of Allergy and Clinical Immunology, 2016, 71, 416-420.	2.7	4
161	Interplay between bile acid metabolism and microbiota in irritable bowel syndrome. Neurogastroenterology and Motility, 2016, 28, 1330-1340.	1.6	103
162	Identification of an anti-inflammatory protein from Faecalibacterium prausnitzii, a commensal bacterium deficient in Crohn's disease. Gut, 2016, 65, 415-425.	6.1	585

#	ARTICLE	IF	CITATIONS
163	Toward Rational Donor Selection in Faecal Microbiota Transplantation for IBD. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 375-376.	0.6	9
164	The presence of the anti-inflammatory protein MAM, from <i>Faecalibacterium prausnitzii</i> , in the intestinal ecosystem. <i>Gut</i> , 2016, 65, 882.1-882.	6.1	32
165	Fungal Dysbiosis in Mucosa-associated Microbiota of Crohn's Disease Patients. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 296-305.	0.6	252
166	Identification of novel anti-inflammatory probiotic strains isolated from pulque. <i>Applied Microbiology and Biotechnology</i> , 2016, 100, 385-396.	1.7	54
167	Faecal microbiota transplantation in recurrent <i>Clostridium difficile</i> infection: Recommendations from the French Group of Faecal microbiota Transplantation. <i>Digestive and Liver Disease</i> , 2016, 48, 242-247.	0.4	53
168	Microorganisms linked to inflammatory bowel disease-associated dysbiosis differentially impact host physiology in gnotobiotic mice. <i>ISME Journal</i> , 2016, 10, 460-477.	4.4	100
169	Targeting the Microbiome in Inflammatory Bowel Disease: Critical Evaluation of Current Concepts and Moving to New Horizons. <i>Digestive Diseases</i> , 2015, 33, 105-112.	0.8	28
170	Benefit of Infliximab Reintroduction after Successive Failure of Infliximab and Adalimumab in Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2015, 9, 349-355.	0.6	16
171	Inflammatory bowel disease after allogeneic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2015, 50, 1365-1366.	1.3	6
172	Identification of Metabolic Signatures Linked to Anti-Inflammatory Effects of <i>Faecalibacterium prausnitzii</i> . <i>MBio</i> , 2015, 6, .	1.8	206
173	<i>Faecalibacterium prausnitzii</i> prevents physiological damages in a chronic low-grade inflammation murine model. <i>BMC Microbiology</i> , 2015, 15, 67.	1.3	208
174	<i>Lactobacillus rhamnosus</i> CNCM I-3690 and the commensal bacterium <i>Faecalibacterium prausnitzii</i> A2-165 exhibit similar protective effects to induced barrier hyper-permeability in mice. <i>Gut Microbes</i> , 2015, 6, 1-9.	4.3	143
175	Gut Fungal Microbiota. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 656-665.	0.9	93
176	Factors Associated with Durable Response to Infliximab in Crohn's Disease 5 Years and Beyond. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 60-70.	0.9	34
177	Changes in the Lönnemann Index Values During the First Years of Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 1633-1640.e3.	2.4	47
178	Indoleamine 2,3-Dioxygenase Fine-Tunes Immune Homeostasis in Atherosclerosis and Colitis through Repression of Interleukin-10 Production. <i>Cell Metabolism</i> , 2015, 22, 460-471.	7.2	107
179	An Image-Based Genetic Assay Identifies Genes in T1D Susceptibility Loci Controlling Cellular Antiviral Immunity in Mouse. <i>PLoS ONE</i> , 2014, 9, e108777.	1.1	6
180	Effects in the use of a genetically engineered strain of <i>Lactococcus lactis</i> delivering in situ IL-10 as a therapy to treat low-grade colon inflammation. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 1611-1621.	1.4	65

#	ARTICLE	IF	CITATIONS
181	Bacterial protein signals are associated with Crohn's disease. <i>Gut</i> , 2014, 63, 1566-1577.	6.1	80
182	Probiotics and Antibiotics in IBD. <i>Digestive Diseases</i> , 2014, 32, 10-17.	0.8	43
183	ImmunoChip SNP array identifies novel genetic variants conferring susceptibility to candidaemia. <i>Nature Communications</i> , 2014, 5, 4675.	5.8	76
184	CD4CD8 ⁺ Lymphocytes, A Novel Human Regulatory T Cell Subset Induced by Colonic Bacteria and Deficient in Patients with Inflammatory Bowel Disease. <i>PLoS Biology</i> , 2014, 12, e1001833.	2.6	117
185	The impact of cytomegalovirus reactivation and its treatment on the course of inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 712-720.	1.9	59
186	The Commensal Bacterium <i>Faecalibacterium prausnitzii</i> Is Protective in DNBS-induced Chronic Moderate and Severe Colitis Models. <i>Inflammatory Bowel Diseases</i> , 2014, 20, 417-430.	0.9	204
187	Complications and surgery in the inflammatory bowel diseases biological era. <i>Current Opinion in Gastroenterology</i> , 2014, 30, 378-384.	1.0	46
188	Alterations in the Intestinal Microbiome (Dysbiosis) as a Predictor of Relapse After Infliximab Withdrawal in Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2014, 20, 1.	0.9	160
189	Ecology and metabolism of the beneficial intestinal commensal bacterium <i>Faecalibacterium prausnitzii</i> . <i>Gut Microbes</i> , 2014, 5, 146-151.	4.3	128
190	Impact of the diagnosis and treatment of cancer on the course of inflammatory bowel disease. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 819-824.	0.6	28
191	Letter: not the end of the role of anti-viral therapy in ulcerative colitis with cytomegalovirus reactivation – authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 1247-1248.	1.9	0
192	Risk of new or recurrent cancer under immunosuppressive therapy in patients with IBD and previous cancer. <i>Gut</i> , 2014, 63, 1416-1423.	6.1	122
193	Impact of Probiotics on Risk Factors for Cardiovascular Diseases. A Review. <i>Critical Reviews in Food Science and Nutrition</i> , 2014, 54, 175-189.	5.4	75
194	Prevalence and risk factors of <i>Clostridium difficile</i> infection in patients hospitalized for flare of inflammatory bowel disease: A retrospective assessment. <i>Digestive and Liver Disease</i> , 2014, 46, 1086-1092.	0.4	40
195	Extra-intestinal malignancies in inflammatory bowel disease: Results of the 3rd ECCO Pathogenesis Scientific Workshop (III). <i>Journal of Crohn's and Colitis</i> , 2014, 8, 31-44.	0.6	130
196	Crohn's disease of the vulva. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 563-570.	0.6	87
197	P1268 IMPACT OF DIET ON GUT MICROBIOTA AND LIVER PHENOTYPE IN CFTR KNOCKOUT MICE. <i>Journal of Hepatology</i> , 2014, 60, S512.	1.8	0
198	Beneficial Effects of Exclusive Enteral Nutrition in Crohn's Disease Are not Mediated by <i>Faecalibacterium prausnitzii</i> . <i>Inflammatory Bowel Diseases</i> , 2014, 20, E18.	0.9	5

#	ARTICLE	IF	CITATIONS
199	Outcomes of Fecal Microbiota Transplantation for <i>C. difficile</i> Infection in Patients With Inflammatory Bowel Disease: Presidential Poster. <i>American Journal of Gastroenterology</i> , 2014, 109, S487.	0.2	1
200	Card9 Mediates Intestinal Epithelial Cell Restitution, T-Helper 17 Responses, and Control of Bacterial Infection in Mice. <i>Gastroenterology</i> , 2013, 145, 591-601.e3.	0.6	131
201	Faecalibacterium prausnitzii and human intestinal health. <i>Current Opinion in Microbiology</i> , 2013, 16, 255-261.	2.3	829
202	Gastrointestinal manifestations in mastocytosis: A study of 83 patients. <i>Journal of Allergy and Clinical Immunology</i> , 2013, 132, 866-873.e3.	1.5	66
203	Efficacy and safety of thalidomide in patients with inflammatory manifestations of chronic granulomatous disease: A retrospective case series. <i>Journal of Allergy and Clinical Immunology</i> , 2013, 132, 997-1000.e4.	1.5	26
204	Connecting dysbiosis, bile-acid dysmetabolism and gut inflammation in inflammatory bowel diseases. <i>Gut</i> , 2013, 62, 531-539.	6.1	663
205	Long-term Outcome of Patients With Crohn's Disease Who Respond to Azathioprine. <i>Clinical Gastroenterology and Hepatology</i> , 2013, 11, 389-394.	2.4	60
206	Decreased Lymphatic Vessel Density Is Associated With Postoperative Endoscopic Recurrence in Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 2084-2090.	0.9	48
207	Factors affecting outcomes in Crohn's disease over 15 years. <i>Gut</i> , 2012, 61, 1140-1145.	6.1	108
208	p40 ^{phox} Expression Regulates Neutrophil Recruitment and Function during the Resolution Phase of Intestinal Inflammation. <i>Journal of Immunology</i> , 2012, 189, 3631-3640.	0.4	46
209	Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment. <i>Genome Biology</i> , 2012, 13, R79.	13.9	2,258
210	Crosstalk between the hepatologist and the cardiologist: A future place for the lithocholic acid as a coronary atheroma risk factor?. <i>Hepatology</i> , 2012, 56, 2426-2426.	3.6	17
211	Anti-inflammatory properties of dairy lactobacilli. <i>Inflammatory Bowel Diseases</i> , 2012, 18, 657-666.	0.9	68
212	Current smoking differentially affects blood mononuclear cells from patients with Crohn's disease and ulcerative colitis: Relevance to its adverse role in the disease. <i>Inflammatory Bowel Diseases</i> , 2012, 18, 1101-1111.	0.9	40
213	Excess primary intestinal lymphoproliferative disorders in patients with inflammatory bowel disease. <i>Inflammatory Bowel Diseases</i> , 2012, 18, 2063-2071.	0.9	96
214	Colorectal neoplasia in PSC-IBD patients: are times changing?. <i>Liver International</i> , 2012, 32, 175-176.	1.9	1
215	Increase in fecal primary bile acids and dysbiosis in patients with diarrhea-predominant irritable bowel syndrome. <i>Neurogastroenterology and Motility</i> , 2012, 24, 513.	1.6	209
216	Clinical, serological and genetic predictors of inflammatory bowel disease course. <i>World Journal of Gastroenterology</i> , 2012, 18, 3806.	1.4	75

#	ARTICLE	IF	CITATIONS
217	How to Identify High-Risk Patients in Inflammatory Bowel Disease?. , 2012, , 713-725.		0
218	Dysbiosis in Inflammatory Bowel Disease: A Link With Antimicrobial Peptides Secretion?. Gastroenterology, 2011, 140, S-328.	0.6	1
219	Air mass pushing the liver. Digestive and Liver Disease, 2011, 43, 1025.	0.4	0
220	Excess Intestinal Lymphoproliferative Disorders in IBD. Gastroenterology, 2011, 140, S-42.	0.6	3
221	Crohn's Disease Associated Dysbiosis as a Predictive Factor of Clinical Relapse: A Microbiological Substudy of the GETAID-STORI Cohort. Gastroenterology, 2011, 140, S-48.	0.6	1
222	Predictors of a 15-Year Non Severe Course in Crohn's Disease. Gastroenterology, 2011, 140, S-777.	0.6	0
223	The intestinal microbiota in inflammatory bowel diseases: time to connect with the host. Current Opinion in Gastroenterology, 2010, 26, 327-331.	1.0	133
224	Intragastric administration of a superoxide dismutase-producing recombinant Lactobacillus casei BL23 strain attenuates DSS colitis in mice. International Journal of Food Microbiology, 2010, 144, 35-41.	2.1	117
225	Current Smoking, Not Duration of Remission, Delays Crohn's Disease Relapse Following Azathioprine Withdrawal. Inflammatory Bowel Diseases, 2010, 16, 362-363.	0.9	12
226	Appendicitis, not appendectomy, is protective against ulcerative colitis, both in the general population and first-degree relatives of patients with IBD. Inflammatory Bowel Diseases, 2010, 16, 356-357.	0.9	14
227	Body mass index and disease activity at treatment initiation. Inflammatory Bowel Diseases, 2010, 16, 714-715.	0.9	2
228	Gastrointestinal involvement and manifestations in systemic mastocytosis. Inflammatory Bowel Diseases, 2010, 16, 1247-1253.	0.9	88
229	Sera from patients with Crohn's disease break bacterial lipopolysaccharide tolerance of human intestinal epithelial cells via MD-2 activity. Innate Immunity, 2010, 16, 381-390.	1.1	13
230	Acute cryptosporidiosis as a cause of sudden recurrence of digestive symptoms in patients with Crohn's disease. Journal of Crohn's and Colitis, 2010, 4, 669-670.	0.6	11
231	Unilateral carotid granulomatous arteritis and Crohn's disease. Revue Neurologique, 2010, 166, 542-546.	0.6	7
232	Risk Factors for Neoplasia in Inflammatory Bowel Disease Patients With Pancolitis. American Journal of Gastroenterology, 2010, 105, 2405-2411.	0.2	69
233	Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy. Gut, 2010, 59, 1363-1368.	6.1	155
234	Crypt abscess-associated microbiota in inflammatory bowel disease and acute self-limited colitis. World Journal of Gastroenterology, 2010, 16, 583.	1.4	18

#	ARTICLE	IF	CITATIONS
235	Inflammatory bowel disease and lymphoproliferative disorders: the dust is starting to settle. <i>Gut</i> , 2009, 58, 1427-1436.	6.1	66
236	Thalidomide as a Treatment for Refractory CGD Colitis. <i>American Journal of Gastroenterology</i> , 2009, 104, 1069-1069.	0.2	10
237	Single Immunoglobulin Infusion Can Reverse Hemodynamic Failure Associated With Severe <i>Clostridium difficile</i> Colitis. <i>American Journal of Gastroenterology</i> , 2009, 104, 2649-2650.	0.2	2
238	Plexitis as a predictive factor of early postoperative clinical recurrence in Crohn's disease. <i>Gut</i> , 2009, 58, 1218-1225.	6.1	101
239	Noncolorectal Malignancies in Inflammatory Bowel Disease: More than Meets the Eye. <i>Digestive Diseases</i> , 2009, 27, 375-381.	0.8	21
240	Epstein-Barr virus-associated lymphoproliferation awareness in hemophagocytic syndrome complicating thiopurine treatment for Crohn's disease. <i>Inflammatory Bowel Diseases</i> , 2009, 15, 1449-1451.	0.9	21
241	Effects of light smoking consumption on the clinical course of Crohn's disease. <i>Inflammatory Bowel Diseases</i> , 2009, 15, 734-741.	0.9	76
242	Low counts of <i>Faecalibacterium prausnitzii</i> in colitis microbiota. <i>Inflammatory Bowel Diseases</i> , 2009, 15, 1183-1189.	0.9	1,052
243	Incidence of benign upper respiratory tract infections, HSV and HPV cutaneous infections in inflammatory bowel disease patients treated with azathioprine. <i>Alimentary Pharmacology and Therapeutics</i> , 2009, 29, 1106-1113.	1.9	72
244	Toll-like receptor 2 is critical for induction of Reg3A expression and intestinal clearance of <i>Yersinia pseudotuberculosis</i> . <i>Gut</i> , 2009, 58, 771-776.	6.1	93
245	Is there any place for alimentary probiotics, prebiotics or synbiotics, for patients with inflammatory bowel disease?. <i>Molecular Nutrition and Food Research</i> , 2008, 52, 906-912.	1.5	35
246	Analysis of bacterial bowel communities of IBD patients: What has it revealed?. <i>Inflammatory Bowel Diseases</i> , 2008, 14, 858-867.	0.9	193
247	<i>Faecalibacterium prausnitzii</i> is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 16731-16736.	3.3	3,581
248	Disease activity and cancer risk in inflammatory bowel disease associated with primary sclerosing cholangitis. <i>World Journal of Gastroenterology</i> , 2008, 14, 3497.	1.4	87
249	Molecular comparison of dominant microbiota associated with injured versus healthy mucosa in ulcerative colitis. <i>Gut</i> , 2007, 56, 152-154.	6.1	40
250	Pure Ileal Crohn's Disease Without Colonic Involvement After a Long Ileo-colonic Anastomosis (Lester) Tj ETQq0 0 0 rgBT /Overlock 1 in a Subset of Patients with Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2007, 13, 243-244.	0.9	8
251	Temperature Gradient Gel Electrophoresis of Fecal 16S rRNA Reveals Active <i>Escherichia coli</i> in the Microbiota of Patients with Ulcerative Colitis. <i>Journal of Clinical Microbiology</i> , 2006, 44, 3172-3177.	1.8	131
252	Specificities of the fecal microbiota in inflammatory bowel disease. <i>Inflammatory Bowel Diseases</i> , 2006, 12, 106-111.	0.9	373

#	ARTICLE	IF	CITATIONS
253	Renal Cortical Necrosis Related to Paraneoplastic Antiphospholipid Syndrome. American Journal of Kidney Diseases, 2006, 47, 1072-1074.	2.1	6
254	Biopsy-proven anuric acute tubular necrosis associated with vancomycin and one dose of aminoglycoside. Nephrology Dialysis Transplantation, 2004, 19, 1921-1922.	0.4	19
255	Specificities of the intestinal microbiota in patients with inflammatory bowel disease and Clostridium difficile infection. , 0, .		1
256	Specific gut microbiota taxa as a key source of variability in colitis model. Nature Reviews Gastroenterology and Hepatology, 0, , .	8.2	0